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Abstract: Numerous molecular abnormalities contribute to the genetic derangements 
involved in tumorigenesis. Chromosomal translocations are a frequent source of these 
derangements, producing unique fusion proteins with novel oncogenic properties. EWS/ETS 
fusions in Ewing sarcoma are a prime example of this, resulting in potent chimeric 
oncoproteins with novel biological properties and a unique transcriptional signature 
essential for oncogenesis. Recent evidence demonstrates that EWS/FLI, the most common 
EWS/ETS fusion in Ewing sarcoma, upregulates gene expression using a GGAA microsatellite 
response element dispersed throughout the human genome. These GGAA microsatellites 
function as enhancer elements, are sites of epigenetic regulation and are necessary for 
EWS/FLI DNA binding and upregulation of principal oncogenic targets. An increasing 
number of GGAA motifs appear to substantially enhance EWS/FLI-mediated gene 
expression, which has compelling biological implications as these GGAA microsatellites 
are highly polymorphic within and between ethnically distinct populations. Historically 
regarded as junk DNA, this emerging evidence clearly demonstrates that microsatellite 
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DNA plays an instrumental role in EWS/FLI-mediated transcriptional regulation  
and oncogenesis in Ewing sarcoma. This unprecedented role of GGAA microsatellite  
DNA in Ewing sarcoma provides a unique opportunity to expand our mechanistic 
understanding of how EWS/ETS fusions influence cancer susceptibility, prognosis and 
transcriptional regulation.  
Keywords: EWS/FLI; ETS family transcription factors; transcriptional regulation; 
oncogenesis; microsatellite DNA; microsatellite polymorphisms 
 
1. Introduction 
Aberrant chromosomal translocations are common observations in cancer and in many instances 
these events give rise to chimeric fusion products with novel biological and cellular functions. Many of 
these chimeric fusion proteins function as oncogenic transcription factors, essential for cellular 
transformation and/or critical malignant cellular phenotypes [1,2]. Ewing sarcoma is a highly 
aggressive bone associated malignancy primarily affecting children and young adults, ubiquitously 
characterized by and derived from a balanced chromosomal translocation [3,4]. Ewing sarcoma 
belongs to a larger class of malignancies referred to as sarcomas, a term ascribed to a heterogeneous 
grouping of tumors derived from, or highly associated with connective tissue elements and 
mesenchymal precursors (Figure 1). Ewing sarcoma is an aggressive malignancy, with significant 
metastatic potential. Roughly 20% of patients present clinically with detectable metastatic disease, 
where survival ranges from 60?75% in patients with localized disease and plummets to <20% in those 
with local recurrence or metastatic disease [3,5].  
Virtually all Ewing sarcoma tumors harbor a somatic translocation, fusing the EWSR1 gene 
(encoding the EWS protein) on chromosome 22 with a member of the ETS family of transcription 
factors, most commonly FLI1 (encoding the FLI protein), located on chromosome 11 [t(11;22)(q24;q12)]. 
The EWS/FLI fusion product is observed in 80?85% of cases, with highly related fusions such as 
EWS/ERG, EWS/FEV, EWS/ETV1 and EWS/ETV4 occurring less frequently (reviewed in Sankar 
and Lessnick, 2011 [6]). In Ewing sarcoma, chimeric EWS/ETS fusion products function as an 
aberrant oncogenic transcription factor, mediated by the transcriptional activating amino-terminus of 
EWS fused in frame to the DNA binding carboxy-terminus of the ETS transcription factor (Figure 2). 
Numerous studies have since confirmed that malignant transformation in Ewing sarcoma is dependent 
on EWS/ETS fusions and consequently, these chimeric oncoproteins are regarded as critical upstream 
regulators of the transcriptional hierarchy in this cancer [7?9]. The prevailing influence of EWS/FLI in 
Ewing sarcoma provides a unique opportunity to further characterize the oncogenic properties of 
EWS/ETS proteins, with hope that this growing body of knowledge will allow for a greater 
understanding of the molecular basis of oncogenesis and facilitate the development of more targeted, 
clinically efficacious therapy for this devastating malignancy. 
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Figure 1. Ewing sarcoma is an aggressive bone associated malignancy characterized by 
chromosomal translocations. (a) Classic radiographic appearance of Ewing sarcoma: an 
expansile, destructive lesion (outlined by white arrows) of the femoral diaphysis (shaft) in 
a skeletally immature patient. Ewing sarcomas can also present as an isolated soft tissue 
mass, although this is less common; (b) 400× magnification of a Hematoxylin and Eosin 
(H & E) stained section from a Ewing sarcoma tumor. Microscopically, these tumors are 
characterized by sheets of small round cells with a high nuclear-to cytoplasmic ratio;  
(c) Break-apart Fluorescence in situ Hybridization (FISH) showing EWSR1 rearrangements in 
84% of tumors cells, confirming the diagnosis of Ewing sarcoma. Dual, non-overlapping, 
??-EWSR1 ???????????????????-EWSR1 probes (green) detect the presence of a chromosomal 
rearrangement; when the red and green probes are split into two distinct signals (white 
arrows) a chromosomal rearrangement is identified, whereas an orange signal indicates an 
intact EWSR1 locus. 
 
Figure 2. EWS/ETS fusions in Ewing sarcoma. EWS/FLI fusions comprise 80?85% of all 
translocations in Ewing sarcoma. Translocations involving other ETS family members such 
as ERG, ETV4, ETV1 and FEV1 are less common. In all instances, the transcriptional 
activating domain (TAD) in the N-terminus of EWS is fused to the C-terminal DNA binding 
domain (DBD) of the ETS family member. The resultant chimeric fusion protein functions 
as a potent oncogenic transcription factor responsible for tumorigenesis in Ewing sarcoma. 
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2. ETS Family of Transcription Factors 
The ETS (E-twenty-six) transcription factors belong to a family of highly evolutionarily conserved 
DNA binding proteins instrumental for a variety of critical cellular processes including proliferation, 
cellular differentiation, angiogenesis, lymphoid cell development, apoptosis and cell migration 
(reviewed in ref [10]). Given these important functions, it is of no surprise that dysregulation of 
numerous ETS family members is commonly observed in cancer. For example, in 50?70% of prostate 
cancers, chromosomal rearrangements involving ETS-members have been observed [11,12]. In many 
instances, these rearrangements position the androgen-receptor regulatory element, TMPRSS2, directly 
upstream of the ETS-member, ERG, resulting in a hormone-driven overexpression of this transcription 
factor in prostate cells [11]. In contrast, as this review will expand upon, fusion of the ETS-DNA 
binding to the transcriptional activating domain of EWS in Ewing sarcoma results in a transcription 
factor with unique biological properties responsible for oncogenic transformation [7,13,14].  
Twenty-eight distinct ETS-family members have been identified in humans, which are further 
categorized into four ETS-subfamilies of more highly related members [15,16]. Common to all ETS-family 
members is a highly conserved DNA binding domain referred to as the ?ETS domain.??Structurally, this 
?ETS domain???????????????????-turn-helix DNA binding domain composed of about 85 amino acids [17]. 
This highly conserved DNA binding domain permits binding of ETS-family members to an invariable 
GGAA/T core DNA target, flanked by nucleotides which facilitate specific ETS-member targeting and 
cooperative protein-protein interactions [16,18,19]. Two general categories of ETS binding sites have 
been characterized, which include a high-affinity ETS consensus site located 20?40 bp upstream of the 
transcriptional start site and a lower affinity consensus site further upstream in the promoter/enhancer 
element [15,16]. The high-affinity ETS consensus sites afford redundant ETS-member occupancy and 
gene regulation, are protected from DNA methylation and are associated with basal housekeeping 
genes. In comparison, the low-affinity sites are modified by simple flanking base substitutions, are 
frequently adjacent to binding sites for other cooperative transcription factors and are felt to provide a 
mechanism where individual ETS-members can regulate a distinct cell or tissue-specific transcriptional 
signature [15,16,20]. 
3. EWS/FLI in Ewing Sarcoma 
EWS/FLI and EWS/ERG fusions compromise 80?85% and 5?10% of translocations observed in 
Ewing sarcoma, respectively [6,13]. Wild-type FLI and ERG are closely related proteins grouped 
within the ETS class I subfamily. As with other ETS-members, they bind DNA with preference for the 
traditional ETS high-affinity consensus sequence (ACCGGAAGT) via the highly conserved C-terminal 
?????????????????????????????????-terminus transcriptional activating domain [7,21]. Both function 
as important regulators of hematopoiesis, B-cell development and vasculogenesis [22?24]. Given the 
predominance of EWS/FLI fusions in Ewing sarcoma, the biology of wild type and fusion-associated 
FLI has been most thoroughly characterized. In contrast, the precise biology of wild type EWS remains 
ill-defined, however reports indicate wild type EWS functions as an RNA binding protein and 
participates in alternative RNA splicing [25?27].  
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Functional investigations over the last two decades clearly demonstrate that the biological 
properties of the EWS/FLI chimera are vastly distinct from wild-type FLI. For instance, while both 
FLI and EWS/FLI share affinity for the ETS consensus site, the EWS/FLI chimera is a substantially 
more potent transcriptional activator than wild-type FLI [7,14]. Additionally, ectopic expression of 
EWS/FLI in NIH 3T3 fibroblasts induces oncogenic transformation whereas wild-type FLI does not [14]. 
Silencing of EWS/FLI expression in patient-derived Ewing sarcoma cell lines reverses the oncogenic 
phenotype [8,28]. Interestingly, wild-type FLI is not expressed in Ewing sarcoma cells [8]. Furthermore, 
the transcriptional signature and genomic targeting of EWS/FLI in Ewing sarcoma is markedly 
different from wild-type FLI [29], despite a shared affinity for ETS consensus sites [14,30].  
4. EWS/FLI Fusions Mediate Gene Dysregulation via a GGAA Microsatellite Response Element 
Genome-wide microarrays have identified >1000 EWS/FLI-regulated genes, including indirect  
and direct gene targets [8,28,31]. Interestingly, ~80% of these are down-regulated targets. Subsequent 
chromatin immunoprecipitation approaches, including ChIP-chip and ChIP-seq have further characterized 
many direct EWS/FLI targets [29,32,33]. Many of the identified up- and down-regulated targets are 
associated with oncogenic processes described in a variety of other cancer models. However, the most 
highly regulated and bound target observed across multiple data sets is the gene NR0B1 (also called 
DAX1) [8,28,33]. NR0B1 is an orphan nuclear receptor, a member of the sex-steroid receptor family, 
and is important for development of the hypothalamus-pituitary-adrenal-gonadal axis and sex 
determination [34,35]. NR0B1 has no prior associated role in oncogenesis, which is compelling given 
the results of the aforementioned microarray and ChIP-chip datasets. Interestingly, NR0B1 is not 
bound or transcriptionally regulated by wild-type FLI [29,36]. Numerous independent reports have 
further validated that NR0B1 is upregulated, a direct EWS/FLI target, and highly expressed in Ewing 
sarcoma. Additional functional assessments have shown that in patient-derived Ewing sarcoma cell 
lines, dysregulated NR0B1 expression is necessary for oncogenic transformation [28,32,33,36,37].  
Genome-wide localization studies have established that EWS/FLI highly occupies the NR0B1 
promoter. Mutational experiments have further demonstrated that a 500 bp region, roughly ?1.6 kb 
upstream from the NR0B1 transcriptional start site is required for EWS/FLI-mediated DNA binding 
and gene activation [32]. Within this 500 bp region is a 102 bp microsatellite characterized by a  
series of repetitive GGAA tetra-nucleotide repeats. Numerous investigations have demonstrated that 
EWS/FLI-mediated binding and activation of NR0B1 is dependent on this repetitive element [32,33,37]. 
Interestingly, the highly enriched NR0B1 promoter does not contain the traditional high-affinity ETS 
consensus site (ACCGGAAGT) [32,33]. Luciferase reporter constructs and electrophoretic mobility 
shift assays (EMSA) have further validated the in vitro specificity and affinity of EWS/FLI for both 
the 102 bp NR0B1 GGAA microsatellite and similar synthetic GGAA microsatellite constructs [30,32]. 
This data provides compelling evidence that the GGAA microsatellite of the NR0B1 promoter 
?????????????????EWS/FLI response element?????????????????????????????????????????????????????????
twenty-eight distinct ETS-members in humans, only 5 have been observed in chromosomal rearrangements 
with EWS in Ewing sarcoma (EWS/FLI, EWS/ERG, EWS/FEV, EWS/ETV1 and EWS/ETV4). All of 
these related fusion proteins are capable of binding the 102 bp NR0B1 GGAA microsatellite and 
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activate gene expression [30,32]. Wild-type ETS-members can also bind the GGAA microsatellite; 
however, unlike EWS/ETS fusions, binding to these elements does not activate gene expression [30]. 
5. Microsatellite Constitution Influences EWS/FLI Binding and Gene Activation  
ETS family members are commonly known to bind DNA in a monomeric configuration  
with a characteristic DNAase I footprint of 14?15 bp, although only 9?10 bp are required for sequence 
specificity [38]. At the aforementioned high-affinity DNA sites, ETS-members bind as monomers, 
whereas at the lower-affinity, divergent DNA sites, ETS-members often bind as heterodimers in  
a cooperative fashion with other cell/lineage specific transcription factors [16]. In Ewing sarcoma, 
EWS/FLI appears to bind to GGAA microsatellites as a homodimer and requires a minimum of  
4 consecutive GGAA motifs (16 bp) for binding and gene activation [30,32]. Importantly, beyond a 
threshold of 4?6 repeats, an increasing number of GGAA motifs results in a proportional increase in 
EWS/FLI-mediated gene expression in both synthetic reporter constructs and bona fide targets, such as 
NR0B1 (Figure 3) [29,30,32,33,36,37]. Genome-wide localization data further supports these observations, 
as sites of EWS/FLI enrichment are greatest in regions with microsatellite elements containing 12?14 
consecutive GGAA motifs [29,33].  
Figure 3. EWS/ETS fusion proteins bind DNA and regulate gene expression via a GGAA 
microsatellite response element. (a) In luciferase reporter constructs, all five EWS/ETS 
fusions can activate gene expression via the 102 bp NR0B1 microsatellite; (b) Using 
similar reporter constructs, an increasing number of GGAA motifs, beyond a threshold of 
four, results in increased gene expression. Panel A reproduced with permission from 
Gangwal et al., Genes Cancer. 2010 February 1; 1(2): 177?187 [30]. 
 
Collectively, these findings demonstrate an unprecedented role for microsatellite elements as direct 
EWS/FLI-transcriptional response elements in Ewing sarcoma. Because an increasing number of 
GGAA motifs substantially augments target gene expression, it is possible that the EWS/FLI chimeric 
protein has an increased affinity for larger microsatellites. Alternatively, larger microsatellites may 
facilitate the recruitment of additional EWS/FLI homodimers to produce a synergistic effect on 
transcriptional activation. Further studies are needed to evaluate these potential mechanisms (Figure 4). 
Genes 2012, 3 450 
 
 
Figure 4. The EWS/FLI chimera possesses unique DNA binding affinities and biological 
properties distinct from native ETS family members. Both high- and low-affinity ETS 
DNA binding sites are characterized by a core ACCGGAA/T consensus sequence facilitating 
both ETS-redundant and ETS-divergent transcriptional regulation. In Ewing sarcoma, 
EWS/FLI also binds the traditional ETS-consensus sequence, but shows increased preference 
for a GGAA-containing microsatellite. In certain upregulated targets, this GGAA microsatellite 
response element is required for DNA binding and gene activation, which proportionately 
increases with an increasing number of GGAA motifs. ?????????????????ion factor. 
 
6. GGAA Microsatellites Identify Other Potential EWS/FLI Targets and Epigenetically 
Regulated Enhancer Loci  
The compelling evidence linking EWS/FLI-mediated transcriptional regulation of NR0B1 in Ewing 
sarcoma to a GGAA microsatellite response element prompted the hypothesis that additional  
GGAA microsatellite containing genes may be critical targets for oncogenic transformation or other 
cancer-related phenotypes. By comparing EWS/FLI transcriptional microarray data-sets with  
genome-wide EWS/FLI localization data, numerous microsatellite-containing direct EWS/FLI targets 
have been identified [29,32,33,39]. For examples, in ChIP-chip experiments, a promoter microarray 
was used to assess ~17000 promoters spanning ?5.5. kb to 2.5 kb relative to the transcriptional start 
site, which identified ~900 direct targets. Of the top 134 EWS/FLI-bound genes, a GGAA microsatellite 
was identified in the promoter region of 12 genes [32]. As previously mentioned, the NR0B1 promoter 
was the most highly enriched region, while the remaining GGAA microsatellite-containing genes were 
dispersed throughout the top 134 bound targets in no particular rank distribution. Caveolin-1 (CAV1) 
was another GGAA microsatellite containing EWS/FLI target and encodes a critical membrane-associated 
protein involved in clathrin-independent endocytosis [40]. Dysregulation of CAV1 has been associated 
with the metastases in other cancer models [41] and expression of CAV1 is necessary for maintenance 
of oncogenic transformation in patient-derived Ewing sarcoma cell lines [42]. Using a comprehensive 
computational mapping of the human genome screening for GGAA microsatellites, another GGAA 
microsatellite-containing, upregulated target, GSTM4, was identified. GSTM4 belongs to a family of 
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glutathione detoxifying enzymes and in patient-derived Ewing sarcoma cell lines, GSTM4 expression 
is necessary for maintenance of oncogenic transformation [39]. Overexpression of this protein also 
increases chemoresistance to a chemotherapeutic agent commonly used in Ewing sarcoma, etoposide [39]. 
Additionally, in a small clinical series, increased expression of GSTM4 in primary Ewing tumors was 
associated with a lower overall survival [39]. Other microsatellite-containing, direct EWS/FLI targets 
such as CACNB2, FEZV1, FCGRT, FVT1/KDSR, ABHD6 and KIAA1797 have also been identified, 
although the functional importance of these targets in Ewing sarcoma has not been determined [32,33]. 
In the ChIP-seq data-set reported by Guillon et al. [33] a total of 246 EWS/FLI occupied regions 
were identified, 104 of which were characterized by a GGAA microsatellite. The vast majority of 
EWS/FLI occupancy was localized to intergenic regions (59%), with less frequent occupancy within 
gene introns, exons and promoter elements. Utilizing published transcriptional microarray data-sets, it 
was determined that 60% of EWS/FLI-specific binding was located within 2 Mb upstream of the 
transcriptional start sites of upregulated EWS/FLI targets. Additionally, the distance of the GGAA 
microsatellite from the transcriptional start site did not correlate with the rank order of gene 
upregulation in these transcriptional microarrays. Instead, as predicted from numerous in vitro assays, 
the number of GGAA motifs within the microsatellite had a greater influence on EWS/FLI occupancy 
and gene expression, which was most pronounced at genomic sites with >9 GGAA motifs [33]. In a 
more recent genome-wide localization study by Patel et al. [29] a combination of ChIP-seq and 
formaldehyde-assisted isolation of regulatory elements (FAIRE) produced a detailed mapping of 
EWS/FLI enrichment sites: 40% of EWS/FLI binding sites contained a GGAA microsatellite, >60% of 
these microsatellite elements were located within intergenic regions and global EWS/FLI-enrichment 
favored microsatellite elements containing 8?14 consecutive GGAA motifs. Greatest enrichment was 
localized to a region containing a total of 25 GGAA motifs, which corresponded to the NR0B1 
promoter. A fascinating observation from this data-set was that EWS/FLI modifies the local chromatin 
structure at these GGAA microsatellites, characterized by a nucleosome-deplete enhancer-like signature. 
Silencing of EWS/FLI rapidly restored nucleosome occupancy and a closed chromatin configuration at 
these GGAA microsatellites [29].  
Collectively, these experiments demonstrate three important mechanistic functions of GGAA 
microsatellites in Ewing sarcoma: first, as response elements instrumental for direct EWS/FLI-mediated 
transcriptional regulation of important oncogenic targets such as NR0B1, CAV1 and GSTM4; secondly, 
the spatial relationship of these GGAA microsatellites to upregulated targets strongly suggests  
these elements possess an enhancer-like function; and finally, these microsatellite elements are regions 
of EWS/FLI-mediated chromatin modification, facilitating a unique transcriptional signature in  
Ewing sarcoma. 
7. The NR0B1 Microsatellite: A Functional Assessment Tool in Ewing Sarcoma Research  
The affinity of EWS/FLI for the NR0B1 GGAA microsatellite and subsequent gene activation 
mediated by this interaction is well established [29,30,32,33,36,37]. Consequently, the NR0B1 GGAA 
microsatellite response element has become a useful molecular tool in Ewing sarcoma research. Since 
EWS/FLI is regarded as the principal upstream oncogenic transcription factor in Ewing sarcoma, it is a 
desirable target for drug development. High-throughput drug and small peptide library screening 
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protocols are effective strategies to simultaneously assess large numbers (10,000?50,000) of therapeutic 
agents potentially active against EWS/FLI. Reporter constructs using the NR0B1 promoter are now 
routinely used as a sensitive measure of EWS/FLI inhibition and have assisted in the identification and 
a more detailed assessment of new drugs and small peptide inhibitors [43?45]. Since the precise cell of 
origin in Ewing sarcoma remains obscure (reviewed in ref [46]), forced expression or repression of 
EWS/FLI in patient-derived Ewing sarcoma cell lines and other heterologous systems is commonly 
employed to assess various cellular pathways of perceived importance in transformation and malignant 
phenotypes. The NR0B1 promoter provides an ideal positive control for various systems of inducible 
EWS/FLI expression (unpublished data). 
8. Microsatellite DNA in Cancer Pathogenesis  
Microsatellite DNA constitutes roughly 3% of the human genome, mostly in non-coding regions [47]. 
Traditionally, these repetitive elements have been r???????? ??? ?????? ?????? ????? ??? ?????????????
genetic function. Microsatellite DNA has been previously investigated as a potential marker of cancer 
susceptibility, genomic instability, and prognosis. However, the direct influence of GGAA microsatellite 
response elements on EWS/FLI-mediated transcriptional regulation of critical targets genes defines a 
completely novel role of microsatellite DNA in oncogenesis.  
Microsatellite instability (MSI) refers to a change in repeat length of microsatellite DNA, typically 
due to loss of heterozygosity in genes coding for the DNA mismatch repair (MMR) system. In 
hereditary non-polyposis colorectal carcinomas (HNPCC) and sporadic colorectal carcinomas, inherited 
or acquired alterations of the DNA mismatch repair system give rise to a mutator phenotype 
characterized by length expansions or contractions of multiple mono- and di-nucleotide microsatellites, 
respectively [48?50]. MSI-positive colorectal tumors possess defined biological attributes, such as a 
more common location in the proximal colon, increased patient survival and favorable patterns of 
chemosensitivity [49?51]. Detection of MSI and defects in the DNA mismatch repair system in 
colorectal cancer has become instrumental for the diagnosis of HNPCC, whereas in sporadic colorectal 
carcinomas, MSI provides an important prognostic molecular marker [52,53]. However, instability of 
these microsatellite sequences is more a manifestation of cancer-related genomic instability and these 
genetic elements do not appear to mediate specific oncogenic transcriptional signatures. Microsatellite 
instability has also been assessed in Ewing sarcoma, although with discordant findings [54?56]. Since 
it is now known that the number of GGAA motifs clearly influences EWS/FLI-mediated gene 
expression in Ewing sarcoma, the determination of MSI in these EWS/FLI microsatellite response 
elements warrants renewed assessment.  
In addition to MSI, microsatellite polymorphisms associated with various genetic loci have also 
been associated to cancer susceptibility and pathogenesis. In breast cancer for example, overexpression 
of the epidermal growth factor receptor, EGFR, is a common finding in invasive ductal carcinomas, 
where EGFR-positive tumors represent an adverse prognostic marker [57,58]. A dinucleotide  
CA-microsatellite within intron 1 of EGFR has been identified and length-polymorphisms of this 
microsatellite have been shown to correlate with basal transcription levels of EGFR [59]; however, a 
direct mechanistic understanding of this association remains unclear. In prostate cancer, a CAG  
tri-nucleotide has been identified in the first exon of the androgen receptor gene, coding for a 
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polyglutamine tract in the translated protein. An increasing number of CAG motifs has been shown to 
reduce the transcriptional activity of the androgen receptor [60]. Polymorphisms of this polyglutamine 
tract in the androgen receptor also appear to be predictive of cancer susceptibility and prognosis: 
androgen receptors with a CAG microsatellite of ?16 CAG motifs are associated with a lower disease 
incidence and less aggressive tumor biology in those with the disease [61,62]. One of the most 
common tumor suppressors, p53 has been shown to regulate the transcriptional regulation of one of its 
targets, PIG3 using a microsatellite response element. However to date, no functional role for PIG3 
has been defined in tumorigenesis [63,64]. 
9. Polymorphic EWS/FLI GGAA Microsatellites: A Novel Approach to Ethnic Patterns of Ewing 
Sarcoma Susceptibility and Prognosis  
At present, compared to many other cancer models, the genetic and environmental risk factors for 
the development of Ewing sarcoma remain obscure [65]. For unknown reasons, considerable ethnic 
variation exists in the incidence of Ewing sarcoma: the incidence of Ewing sarcoma is greatest in 
European populations, which is 10- and 2-fold greater than populations of African and Asian descent, 
respectively [66,67]. This discrepancy is independent of geographic location, suggesting a strong 
genetic influence for these observations [66]. Additionally, a recent database of >1,700 patients with 
Ewing sarcoma demonstrated lower overall survival rates in African and Asian populations [68]. To 
date, no studies have conclusively explained these epidemiological patterns [65,69,70]. 
By virtue of the repetitive constitution of microsatellite DNA and the predilection of these repetitive 
elements for non-coding locations, mutational events have rendered microsatellite DNA highly 
polymorphic in the human population [47,71]. Microsatellite polymorphisms are routinely used in the 
assessment of heredity, and phylogenetic mapping of ethnically distinct human populations [72]. 
Given the mechanistic importance of GGAA microsatellites in EWS/FLI-mediated gene regulation, we 
hypothesized that polymorphic GGAA microsatellites within and between ethnically distinct human 
populations may exist, providing a potential explanation for the aforementioned patterns of Ewing 
sarcoma susceptibility and prognosis. The GGAA microsatellites of the NR0B1 and CAV1 promoters 
were sequenced from 100 unaffected subjects of European and African descent. Our initial hypothesis 
favored larger GGAA microsatellites in Europeans given the disproportionately high incidence of 
Ewing sarcoma in this population. 
Results from this study demonstrated that the NR0B1 and CAV1 GGAA microsatellites were highly 
polymorphic in both European and African populations. The NR0B1 microsatellite was substantially 
more polymorphic than CAV1 in both populations, where the number of GGAA motifs ranged from 
16?60 and 14?72 in Europeans and Africans, respectively. Additionally, while the characteristics of 
the CAV1 promoter microsatellites were similar across both populations, the NR0B1 microsatellite in 
African subjects was significantly larger, harboring more repeat motifs, a greater number of repeat 
segments, and longer consecutive repeats, than in European subjects. The vast majority (>85%) of 
European NR0B1 microsatellites were tightly clustered around smaller repeats ranging from 16?26 
GGAA motifs, whereas 40% of African microsatellites were characterized by large, multi-segment 
repeats ranging from 30?72 GGAA motifs [73]. These results were opposite to our original hypothesis, 
but considering the transcriptional implications of an increasing number of GGAA motifs in these 
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EWS/FLI response elements, these results provoke several biologically intriguing hypotheses: It is 
possible that the massive NR0B1 microsatellites commonly observed in Africans do not permit a 
stoichiometrically favorable environment for EWS/FLI binding and are therefore protective of 
EWS/FLI-mediated NR0B1 gene activation. Alternatively, these large repeats may facilitate a toxic 
level of NR0B1 expression and permit premature cellular termination in the presence of EWS/FLI. It is 
also possible that the increased number of GGAA motifs observed in Africans has no influence on 
Ewing sarcoma susceptibility but instead supports an enhanced oncogenic potential of affected cells, 
contributing to the lower survival rates observed in African populations. 
Polymorphisms of the NR0B1 GGAA microsatellite have been observed across the various Ewing 
sarcoma cell lines, ranging from 16?26 motifs, which approximates the distribution repeats observed in 
Europeans. NR0B1 mRNA levels in the various cell lines is tightly correlated with the number of 
GGAA motifs [37]. Based on this information, it is possible that EWS/FLI has preference for a narrow 
range of GGAA repeats in the NR0B1 microsatellite, a so-??????????????????? with a GGAA-configuration 
conducive to maximal EWS/FLI-mediated gene up-regulation. Given the highly polymorphic nature of 
the NR0B1 microsatellite within and across ethnically distinct populations, functional assessment of 
these massive repeats is needed. Correlating polymorphisms of the NR0B1 GGAA microsatellite in 
tumor samples with clinical parameters such as overall survival, metastatic burden, anatomic location 
and chemosensitivity may provide valuable information and lend to the development of GGAA 
microsatellite polymorphisms as prognostic biomarkers in Ewing sarcoma.  
10. Conclusions  
Chromosomal translocations are common molecular events in cancer, often producing novel fusion 
proteins with oncogenic properties. EWS/ETS chimeras in Ewing sarcoma are prototypical fusion 
products with unique DNA binding and regulatory properties responsible for tumorigenesis. A 
fascinating emergent property of EWS/ETS chimeras is their ability to directly modulate gene 
expression and the local chromatin environment via a tetra-nucleotide, GGAA microsatellite. This not 
only highlights how chimerism vastly alters the biological attributes of involved ETS-members, but 
also brings to attention a completely unappreciated role of microsatellite DNA in oncogenic 
transcriptional regulation. GGAA microsatellites have enabled the identification of novel target genes 
and have become important molecular tools in Ewing sarcoma research. These GGAA microsatellites 
are also highly polymorphic in human populations, and given that EWS/ETS-mediated gene 
expression is highly dependent on the length of these repetitive elements, GGAA microsatellite 
polymorphisms may also provide a unique opportunity to improve our mechanistic understanding of 
disease susceptibility and prognosis in Ewing sarcoma. Certainly, in Ewing sarcoma, elements once 
?????????????????????????????????????????????????????????????????????????????-mediated oncogenesis. 
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